In the human gastrointestinal tract (GI tract), the small intestine is a primary part for an administered drug to penetrate the gastrointestinal mucosa and ride in the blood. The surface area of the small intestine is large and it has been reported to be approximately 463 m 2 which is comparable to a basketball court area. 1, 2) According to the huge surface area, drugs that are well absorbed at the whole sites in the small intestine are given much absorption opportunity after oral administration. However, for drugs that are well absorbed in the stomach or the upper part of the intestinal tract (duodenum, jejunum) such as ciprofloxacin, 3) sotalol HCl 4) and acyclovir, 5) the drug absorption from the GI tract would be influenced by residence time on the absorption sites. For such narrow absorption window drugs, gastroretentive drug delivery systems have been studied to extend the duration time of therapeutic efficacy. In addition, the bioavailability of drugs that are unstable in the intestinal fluid such as captopril, 6) as well as drugs that exhibit poor solubility in the intestinal tract such as diazepam 7) and verapamil HCl 8) could be improved by using the gastroretentive systems.
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Several technologies have been used to achieve gastroretentive dosage forms for the purpose of extending drug residence time in the stomach. Kawashima et al. 9, 10) and Sato et al. 11, 12) prepared floating microspheres using an emulsion solvent diffusion method with enteric acrylic polymers and then investigated their pharmacological properties in humans. 13, 14) Streubel et al. 15) investigated a floating drug delivery system consisting of a low density polypropylene foam powder and matrix-forming polymers. Wei et al. 16 ) studied the properties of floating tablets containing hydroxypropylmethylcellulose and sodium bicarbonate. The CO 2 gas generated when tablets containing sodium bicarbonate were immersed in simulated gastric fluid rendered the tablets buoyant. However, a potential problem with this system was that the tablet could rapidly exit the stomach before becoming buoyant since the device cannot float immediately after administration and its buoyancy will be influenced by fluctuations in the pH of the gastric fluids. Fukuda et al. 17) investigated a rapid and pH independent floating systems using sodium bicarbonate and acrylic polymers by hot-melt extrusion. The cross-sectional morphology of the floating tablets exhibited a porous structure that was formed by utilizing the evolution of CO 2 gas attributable to the thermal decomposition of sodium bicarbonate in softened acrylic polymers at elevated temperature during hot-melt extrusion process. Furthermore, expandable gastroretentive dosage forms have been also reported in the scientific literature.
2)
The purpose of this study was to develop a novel floating sustained release tablet in order to contribute to the growth of gastroretentive drug delivery technologies. Famotidine is a H 2 -receptor antagonist, and it has been reported that the halflife of the drug is short (3 h) and the bioavailability is low (40-45%) due to the incomplete absorption from the GI tract.
18) Therefore, famotidine was chosen as the model drug in our study. L-Menthol is a monocyclic terpenoid which is solid at room temperature, and it has sublimation nature and a low melting point at 42-45°C. The solid state of L-menthol changes to liquid state and evaporates when heated above the melting point. In this study, L-menthol was investigated as a cavity forming agent in tablets. In addition, hydrophobic polymers such as stearyl alcohol, glyceryl monostearate (GMS) and hydrogenated castor oil (Lubri wax ® ), a hydrophilic polymer (hypromellose 2208) and an acrylic polymer (Eudragit ® RS PO) were investigated to retard drug release from tablets in this study. Preparation of Floating Sustained Release Tablets The tablet formulations investigated in the current study are shown in Table 1 . The floating sustained release tablets were prepared according to the method showing in Fig. 1 . L-Menthol crystals were ground to powders using a mortar and pestle for 30 s. The powdered L-menthol (75 mg) was compressed at the pressure of 500 kg using a tabletting apparatus (HT-AP18-SSII, Hata Iron Works Co., Ltd., Kyoto, Japan) equipped with flat-face punches of 6 mm diameter. A 5 g sample of powder containing famotidine and an excipient such as mannitol was blended using a mortar and pestle for 5 min. The blended powder (50 mg) was gently compressed at 10 kg using a tabletting apparatus equipped with flat-face punches of 8.5 mm diameter and a core tablet was placed on the center of the compressed powder. Another blended powder (100 mg) was put and covered them, and then compressed at 500-1200 kg to obtain a dry-coated tablet. Dry-coated tablets were put in an oven (DRS420DA, Toyo Seisakusho Kaisha, Ltd., Chiba, Japan) at 80°C for 90 min to remove the L-menthol core from tablets. Hydrophobic retardant polymers (8 g) such as stearyl alcohol were melted in a 50 ml beaker in a hot water bath maintained at 90°C. The hollow tablets were immersed in the molten polymers for 1 min and removed. The tablets were stored at room temperature for at least 1 min.
Thermal Analysis (TG/DTA) Thermogravimetry/differential thermal analysis (TG/DTA) was carried out using a TG/DTA 6200 (Seiko Instruments Inc., Chiba, Japan) to investigate the thermal properties of tablets before and after heat treatment in an oven at 80°C. A sample of approximately 10 mg was accurately weighed into an aluminum pan (open type) and heated at 5°C/min from 30 to 200°C under N 2 gas flow (100 ml/min) using an empty pan as a reference.
Tablet Density The density (D) of floating tablets was calculated from tablet diameter, height and weight using the following equation.
Here, m is the diameter of a tablet, p is the circular constant, h is the height of a tablet, and w is the weight of a tablet. Buoyancy The buoyancy of tablets was determined using the paddle method at a rotation speed of 100 rpm with a NTR-VS6 Dissolution Tester (Toyama Sangyo Co., Ltd., Osaka, Japan) in 900 ml of 0.01 N HCl at 1222
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In Vitro Drug Release In vitro drug release testing of tablets was conducted according to the United States Pharmacopeia (USP) 32 apparatus 2 (paddle method) using a NTR-VS6 Dissolution Tester. The dissolution medium used was 900 ml of 0.01 N HCl since the famotidine released from tablets was not stable under the strong acidic condition of 0.1 N HCl for long periods. During dissolution testing, the media were maintained at 37Ϯ0.5°C and agitated at 100 rpm. A 10 ml sample of the solution was withdrawn from the dissolution apparatus at time points of 0.5, 1, 2, 3, 4, 5 and 6 h and the samples were replaced with fresh dissolution medium. The samples were then passed through a 0.45 mm membrane filter. Drug concentrations were determined by HPLC. The HPLC system (Alliance HPLC system, Waters Corporation, MA, U.S.A.) consisted of 2695 Separations Module and 2487 Dual l Absorbance Detector. The detection wavelength was set at 254 nm. Elution was performed with a C18 column (Inertsil ® ODS-3, 5 mm, 4.6ϫ250 mm, GL Sciences, Inc., Tokyo, Japan) using 20 mM sodium dihydrogen phosphate/methanol (80 : 20, v/v) with a flow rate of 1.0 ml/min at 30°C. All dissolution tests were performed in triplicate.
Morphological Observation The cross sectional morphologies of drycoated tablets (formulation 1) before and after heat treatment in an oven at 80°C for 90 min were compared using a scanning electron microscope (SEM; Real Surface View Microscope, VE-7800, KEYENCE Corporation, Osaka, Japan) at an accelerating voltage of 2 kV and a digital camera (Coolpix 4300, Nikon Corporation, Tokyo, Japan).
Results and Discussion
Influence of Excipients in Outer Layer of Tablets on LMenthol Core Removal Five excipients of mannitol, microcrystalline cellulose, lactose hydrate, hypromellose 2208 and Eudragit ® RS PO (formulations 1-5 in Table 1 ) were investigated as excipients for outer layer of dry-coated tablets. The dry-coated tablets prepared from formulations 1-5 were put in an oven at 80°C and the tablet weights were checked every 30 min up to 3 h (Fig. 2) . For mannitol, microcrystalline cellulose and lactose hydrate, L-menthol core was removed completely through pathways in outer layer of tablets in 1 h by melt and sublimation actions of L-menthol at 80°C. However, for hypromellose 2208, the tablet swelled and crumbled since the liquidized L-menthol at elevated temperature functioned like water. This would be similar to the water penetration into sustained release tablets containing hypromellose, although no hydrogels were observed since hydrogen bonds hardly formed between L-menthol and hypromellose due to the low hydrophilic nature of L-menthol. On the other hand, the L-menthol core was not removed when Eudragit ® RS PO was used as an excipient even when put in an oven at 80°C for 3 h. This would be since Eudragit ® RS PO has a glass transition temperature at around 58°C, 17) therefore the soften Eudragit ® RS PO retained the molten Lmenthol at the center of tablets. According to these results, it was found that mannitol, microcrystalline cellulose and lactose hydrate were suitable excipients for this system. However, microcrystalline cellulose and lactose hydrate contain some water such as crystallization water and/or adhesion water, and also it has been known that lactose hydrate would react with compounds having amino group. On the other hand, mannitol is a useful excipient when used with moisture sensitive compounds due to its non-hygroscopicity, and would be compatible with compounds having amino group. Due to these better physicochemical properties, mannitol was chosen as the excipient in outer layer of dry-coated tablets in the following study.
The Change in Thermal Properties Following Floating
Tablet Preparation The influence of heat treatment at 80°C on the thermal properties of dry-coated tablets prepared from formulation 6 was investigated using TG/DTA. The DTA thermograms of dry-coated tablets before and after heat treatment at 80°C for 90 min are shown in Fig. 3a . With the dry-coated tablet before heat treatment, endothermic peaks were observed at approximately 47°C, 153°C and 165°C, which correspond to L-menthol, famotidine and mannitol, respectively. The peak for L-menthol in the tablets after heat treatment was not seen in the DTA profile since L-menthol core was removed completely through pathways in outer layer of dry-coated tablets by melt and sublimation actions at elevated temperature. The TG profiles of dry-coated tablets before and after heat treatment are shown in Fig. 3b . For the dry-coated tablet before heat treatment, 33% of sample weight which is exactly corresponding to L-menthol level in a tablet was decreased due to evaporation of L-menthol. When dry-coated tablets were put in an oven at 80°C for 90 min, no change in the sample weight on the TG profile was observed since L-menthol core was removed by a heat treatment process.
Effect of Polymer Penetration Processing on Famotidine Release To investigate the influence of polymer penetration into tablets on the drug release properties and buoyancy, the floating tablets prepared according to a heat treatment of dry-coated tablets (formulation 6) were immersed into the molten stearyl alcohol at 90°C for only 1 min (formulation 7). A comparison of the drug release rates from floating tablets with and without polymer penetration is shown in Fig. 4 . The tablets without polymer penetration (formulation 6) floated on the surface of the media for a short time and the drug release in 0.01 N HCl was significantly rapid due to rapid disintegration of tablet in media. When tablets were immersed into the molten stearyl alcohol at 90°C for 1 min, the rapid drug release was drastically retarded and the tablets floated on the surface of the media during dissolution testing. This would be attributed to the formation of wax matrices within the shell of tablets.
Influence of Hydrophobic Polymer Type on Famotidine Release To investigate the influence of hydrophobic polymer type on famotidine release from floating tablets, stearyl alcohol, GMS and Lubri wax ® were used (formulations 7-9) and the drug release properties were compared (Fig. 5) . When Lubri wax ® was melted and penetrated into tablets, the tablets exhibited the slowest sustained release properties and floated on the surface of media during the dissolution test.
On the other hand, faster sustained release properties were observed when GMS was used, due to its low hydrophobic nature as compared to other polymers used in this study. The drug release rate from tablets prepared using stearyl alcohol as a hydrophobic polymer exhibited middle rate sustained release properties in this study. In addition, a blend polymer of GMS and Lubri wax ® in the weight ratio of 1 to 1 was also investigated since these two molten polymers were miscible. The drug release rate from the tablets prepared penetrating the polymer blend (formulation 10) was between those from tablets prepared by formulations 8 and 9 (Fig. 6 ). These results suggested that the sustained release rate from floating tablets could be controlled by both the choice of hydrophobic polymer and the combined use of hydrophobic polymers.
Influence of Drug Levels on the Drug Release Properties of Floating Tablets In order to investigate the influence of drug levels on the drug release properties of floating tablets, 30 to 120 mg famotidine was incorporated into the tablets (formulations 10-12) and the drug release properties of tablets were compared (Fig. 7) . The drug release rate from floating tablets tended to decrease with increase in the drug level. When 120 mg famotidine was present in a tablet, the famotidine release rate decreased significantly. This could be attributed to both the increase in the contact area of famotidine with hydrophobic polymer and the decrease in the level of water-soluble excipient, mannitol. The decrease in the drug release rate was independent on tablet hardness and thickness since no significant difference in the tablet densities of formulations 10-12 was observed ( Table 2 ). In addition, for buoyancy testing, the floating tablets prepared from formulations 10-12 were all floating on the media for at least 6 h. This result suggested that the drug level in the floating tablets exhibited no influence on the tablet buoyancy.
Cross Sectional Morphologies The cross sectional morphologies of dry-coated tablets before and after heat treatment at 80°C for 90 min were observed using SEM and digital camera (Fig. 8) . The cross sectional morphologies of tablets after heat treatment exhibited a presence of a cavity in a tablet. This was since the L-menthol was removed through pathways in outer layer of tablets according to melt and sublimation actions at elevated temperature during heat treatment process.
Conclusions
A novel floating sustained release tablet having a cavity in the center was developed by utilizing the physicochemical properties of L-menthol and the penetration of molten hydrophobic polymer into tablets. The hollow internal tablet morphology that contributed to buoyancy was formed by a removal of L-menthol core from a dry-coated tablet attributable to the melt/sublimation actions of L-menthol at 80°C. On the other hand, interestingly, the sustained release properties were easily obtained by a hydrophobic polymer penetration process into the shell of hollow tablets at 90°C for 1 min. The tablets were shown to be buoyant in the media and to possess sustained release properties. In addition, it was also found that the drug release rate from floating tablets could be controlled by both the choice of hydrophobic polymer and the combined use of hydrophobic polymers.
